Dextera Surgical Appoints Mark Soberman M.D., Leader in Thoracic Surgery, as Medical Director
June 29 2016 - 8:00AM
Dextera Surgical Inc. (Nasdaq:DXTR) today announced the appointment
of Mark Soberman, M.D., MBA, FACS, to the position of medical
director. In this role, Dr. Soberman will focus on expanding
Dextera Surgical’s presence in minimally invasive and
robotic-assisted surgery by working with key opinion leaders around
the world to develop techniques for using the MicroCutter 5mm
stapler with 80 degrees of articulation in surgical procedures. He
will also lead the creation of Dextera Surgical’s first clinical
advisory board in thoracic surgery.
A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/c78dcbb7-e679-4742-ac98-691266bcdf68
“Mark’s vast clinical experience and leadership
position within the thoracic surgery community, as well as his deep
understanding of healthcare economics, is a key advantage to
Dextera,” said Julian Nikolchev, president and CEO of Dextera
Surgical. “We are very excited to have Mark join our team at this
critical and exciting time for the company, and know that he will
be instrumental in furthering our commitment to developing tools
that provide significant clinical advantages in the minimally
invasive surgery market.”
Dr. Soberman is a practicing thoracic surgeon who
also serves as medical director of the Oncology Service Line and
chief physician executive, Monocacy Health Partners at Frederick
Regional Health System in Frederick, Md. He is a reviewer for the
Annals of Thoracic Surgery and a member of a variety of surgical,
oncology and physician executive societies, including the Society
of Thoracic Surgeons, General Thoracic Surgical Club, American
College of Healthcare Executives and the American Society for
Clinical Oncology. Additionally, Dr. Soberman serves on the
Executive Committee of the Board of Trustees for the Association of
Community Cancer Centers and is the Association’s president-elect
for 2017.
"There has been very little innovation recently in
surgical stapler technology. The MicroCutter, by virtue of its slim
profile and 80 degrees of articulation, has the potential to
accelerate the advancement of minimally invasive techniques in
thoracic surgery,” said Dr. Soberman. “Dextera is committed to
putting breakthrough technologies in the hands of surgeons as they
work to improve surgical techniques and outcomes, and I am very
pleased to be a part of that effort."
About Dextera
SurgicalDextera Surgical designs and manufactures
proprietary stapling devices for minimally invasive surgical
procedures. In the U.S., surgical staplers are routinely used
in more than one million minimally invasive laparoscopic,
video-assisted or robotic-assisted surgical procedures
annually.
The company’s signature proprietary technology, the
MicroCutter 5/80 Stapler, is the world’s first and only
five-millimeter surgical stapler that articulates to 80 degrees in
each direction. As the smallest-profile articulating stapler
available today, the MicroCutter 5/80 Stapler may reduce the amount
of dissection and tissue handling required to position the stapler
in confined spaces, enabling access to difficult-to-reach
anatomy. The cartridge-based device’s small size and wide
articulation range is designed to enhance the surgeon’s access and
visualization at the surgical site, and to mitigate limitations on
the advancement of minimally invasive surgical approaches created
by larger stapling devices.
Dextera Surgical also markets the only
automated anastomosis devices for coronary artery bypass graft
(CABG) surgery on the market today: the
C-Port® Distal Anastomosis Systems and PAS-Port® Proximal
Anastomosis System. These products, sold by Dextera
Surgical under the Cardica brand name, have demonstrated
long-term reliable clinical performance for more than a decade.
MicroCutter Indication
InformationThe MicroCutter 5/80 Stapler is manufactured
and cleared for use in the United States for transection and
resection in multiple open or minimally invasive urologic, thoracic
and pediatric surgical procedures, as well as application for
transection, resection and/or creation of anastomoses in the small
and large intestine, and the transection of the appendix. The
MicroCutter 30 White Reload has application in vascular
tissue.
Forward-Looking StatementsThe
statements in this press release regarding Dextera Surgical’s
beliefs as to the benefits expected to be obtained from the use of
the MicroCutter 5/80 Stapler, are "forward-looking statements."
There are a number of important factors that could cause results to
differ materially from those indicated by these forward-looking
statements, including: that Dextera Surgical may not be successful
in its efforts to complete the development of its combination
device (designed to use two different size cartridges) or achieve
optimization of Dextera Surgical’s supply chain for its combination
device; that Dextera Surgical may not receive regulatory clearance
for indications not currently cleared; as well as other risks
detailed from time to time in the company’s reports filed with the
U.S. Securities and Exchange Commission, including its Quarterly
Report on Form 10-Q for the quarter ended March 31, 2016, under the
caption “Risk Factors.” Dextera Surgical expressly disclaims any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein. You
are encouraged to read Dextera Surgical’s reports filed with the
U.S. Securities and Exchange Commission, available at
www.sec.gov.
Contact:
Investors:
Bob Newell
Vice President, Finance and Chief Financial Officer
(650) 331-7133
investors@dexterasurgical.com
Media:
Jessica Volchok
(310) 849-7985
jessica@nicoleosmer.com